The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / November / Understanding the Benefits of Gelatin and Collagen
Formulation Development & Clinical Small Molecules Sponsored

Understanding the Benefits of Gelatin and Collagen

Check out our interview from CPHI Frankfurt featuring GELITA’s Samy Jandall

11/27/2025 0 min read Video

Sponsored By

Share

What important roles do gelatin and collagen play in biomedical applications? And why are endotoxin controlled excipients so important? Find out in this interview with Samy Jandall, GVP Global Business Management at the GELITA Group.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Christine Allen
Development & Clinical Small Molecules Interviews
Musings from The Power List: Christine Allen

August 28, 2026

2 min read

Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise

Phase III Success Marks Milestone for Personalized Cancer Vaccines
Biopharma Industry News Development & Clinical
Phase III Success Marks Milestone for Personalized Cancer Vaccines

August 26, 2026

7 min read

Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field

The Biggest Bottlenecks Holding Back Cell and Gene Therapy
Cell & Gene Development & Clinical Business & Trends
The Biggest Bottlenecks Holding Back Cell and Gene Therapy

August 24, 2026

9 min read

Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges

Musings from The Power List: Daniel Vitt
Small Molecules Drug Discovery Development & Clinical
Musings from The Power List: Daniel Vitt

August 20, 2026

6 min read

From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: